Zhou L M, He X S, Li G, de Costa B R, Skolnick P
Laboratories of Neuroscience and Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0008, USA.
J Med Chem. 1995 Dec 8;38(25):4891-6. doi: 10.1021/jm00025a006.
A series of N,N'-substituted piperazine and homopiperazine derivatives have been synthesized with the objective of producing compounds that interact with polyamine modulatory sites on N-methyl-D-aspartate (NMDA) receptors. These novel compounds exhibited polyamine-like actions, enhancing [3H]MK-801 binding to NMDA receptors in rat forebrain membranes. The potencies of N,N'-bis(2-aminoacetyl)homopiperazine (15), N,N'-bis(N-methyl-4-aminobutyl)-piperazine (7), and N,N'-bis(3-aminopropyl)homopiperazine (11) (EC50 18.0, 21.3, and 24.4 microM, respectively) to enhance [3H]MK-801 binding were comparable to that of spermine (EC50 5.2 microM). However, the efficacies of 15, 7, and 11 in this measure were lower (by approximately 40%, 32%, and 24%, respectively) than spermine, which may be indicative of partial agonist actions. Like spermine, the ability of these piperazine and homopiperazine derivatives to enhance [3H]MK-801 binding could be inhibited by both a competitive polyamine antagonist (arcaine) and a specific, noncompetitive polyamine antagonist (conantokin-G). However, unlike endogenous polyamines, high concentrations (up to 1 mM) of these novel polyamine-like compounds did not inhibit [3H]MK-801 binding. N,N'-Aminoalkylated and aminoacylated piperazine and homopiperazine derivatives may prove useful for studying polyamine recognition sites associated with NMDA receptors.
已合成了一系列N,N'-取代的哌嗪和高哌嗪衍生物,目的是制备与N-甲基-D-天冬氨酸(NMDA)受体上的多胺调节位点相互作用的化合物。这些新型化合物表现出多胺样作用,增强了[3H]MK-801与大鼠前脑细胞膜中NMDA受体的结合。N,N'-双(2-氨基乙酰基)高哌嗪(15)、N,N'-双(N-甲基-4-氨基丁基)哌嗪(7)和N,N'-双(3-氨基丙基)高哌嗪(11)增强[3H]MK-801结合的效力(EC50分别为18.0、21.3和24.4 microM)与精胺(EC50 5.2 microM)相当。然而,在此测量中,15、7和11的效力比精胺低(分别约低40%、32%和24%),这可能表明其部分激动剂作用。与精胺一样,这些哌嗪和高哌嗪衍生物增强[3H]MK-801结合的能力可被竞争性多胺拮抗剂(鹅肌肽)和特异性非竞争性多胺拮抗剂(芋螺毒素-G)抑制。然而,与内源性多胺不同,这些新型多胺样化合物的高浓度(高达1 mM)并不抑制[3H]MK-801结合。N,N'-氨基烷基化和氨基酰化的哌嗪和高哌嗪衍生物可能被证明对研究与NMDA受体相关的多胺识别位点有用。